Scimitar Equity Blog

The Vatican on 7/31/10 condemned as “unacceptable” the green light given by the FDA to a clinical trial for a treatment based on human embryonic stem cells. Read more…

After a big rally in July, investors could be in for another bout of economic jitters this week as the focus shifts from earnings to the weak job market. Read more…

NBS has been awarded a $700 K contract  for the purpose of evaluating the use of topically applied bone marrow-derived adult mesenchymal stem cells (MSCs) for rapid wound healing Read more…

On Friday (7/30/10), GERN said the clinical hold on its application has been lifted. The FDA notification enables Geron to move forward with the world’s first clinical trial of a human embryonic stem cell (hESC)-based therapy in man. Read more…

For Q2/10, GERN reported a net loss of $17 M, or $(0.18) per share. Read more…

It’s a huge challenge: skin must be waterproof, flexible and a barrier against infection. Both the cells that make up the outermost layer of the skin and the structure of how the cells fit with each other must be duplicated. So far, no one has figured out how to synthetically make our body’s largest organ. Read more…

PureGraft™ and Celution®  approvals in the EU allows CYTX to offer a broader portfolio of products to plastic and cosmetic surgeons and expanding market opportunity. Read more…

CYTX has received European (CE Mark) approval for the PureGraft™ 250/PURE System for autologous fat grafting procedures, Read more…

ATHX announced positive (7/28/10) results from its phase I clinical trial of MultiStem^(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), Read more…

ISCO.OB’s Lifeline Cell Technology® (Lifeline) and Sristi Biosciences have entered into a distribution agreement for the Lifeline® brand of human cell culture products in India. Read more…